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Background: Risk factors for poor asthma outcomes may have considerable inﬂuence on
the control level and medical care of asthmatic patients. Our objective was to conduct a study
that provides data on the level of symptom control and the frequency of speciﬁc risk factors
for poor asthma outcomes on a large patient cohort.
Methods: A cross-sectional, non-interventional real-life study was conducted among asth-
matic patients treated by respiratory specialists in Hungary. Asthma control and risk factor
assessment were done according to Global Initiative for Asthma guideline (Box 2–2). In the
data analysis, phase descriptive statistics, graphical outputs, and Fisher’s exact tests were
used.
Results: Of 12743 patients enrolled by 187 specialists, asthma was well controlled in 36.0%,
partially controlled in 29.29%, and uncontrolled in 34.71% of the cases. The most common
comorbidities were rhinitis/sinusitis (66.84%), cardiovascular diseases (43.81%), and gastro-
esophageal reﬂux disease (20.11%). The following risk factors had the strongest relationship
with uncontrolled disease: incorrect inhaler technique causing side effects (odds ratio, OR 4.86,
3.51–6.8), previous severe exacerbation (OR 4.79, 4.02–5.72), high short-acting beta agonist
(SABA) use (OR 4.46, 4.03–4.93), incorrect inhaler technique associated with an exacerbation
(OR 3.91, 3.06–5.03), and persistently low forced expiratory volume in 1 s (FEV1, OR 3.14,
2.8–3.52). The most frequent risk factors were smoking (OR 1.47, 1.36–1.59) and obesity (OR
1.34, 1.24–1.45). Furthermore, high loss of control was associated with an initial low FEV1
(OR 2.21, 2.01–2.44), frequent oral corticosteroid (OCS) use (OR 1.83, 1.64–2.05), poor
adherence to treatment (OR 2.51, 2.21–2.86), and allergen exposure (OR 1.63, 1.47–1.81).
Conclusions: This study indicated that the presence of risk factors for poor asthma out-
comes listed by the Global Initiative for Asthma document signiﬁcantly inﬂuenced actual
control level in a real-world large patient cohort, with high SABA use, previous severe
exacerbation, incorrect inhaler technique, persistently low FEV1, and poor adherence to
treatment having the highest impact.
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Background
Asthma is a chronic pulmonary disease with considerable economic burden.1 In
2015, asthma was the most prevalent chronic respiratory disease, affecting 358
million people, meaning twice the number of cases compared to chronic obstructive
pulmonary disease (COPD).2
The prevalence of asthma in Hungary was found to be 7.6%, which corresponds to
the European average.3 International strategies set forth by the Global Initiative for
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Asthma (GINA) document, as well as the local national
asthma guideline, help in effective clinical management and
propose therapeutic decisions to be made based on the level
of asthma control. The aim of asthma treatment is to achieve
a controlled condition and to maintain it on the long term.4
Despite the presence of established treatment guidelines and
high accessibility to inhaled therapies, asthma morbidity is
signiﬁcant, and many asthma patients still experience persis-
tent symptoms, poor disease control, and exacerbations.5,6 A
recent European study of 8000 asthmatic patients treated in
general practice showed that 45% of them were uncontrolled
and 44% required at least 1 course of oral corticosteroids in
the last year.7 Poor asthma control is associated with negative
outcomes, including impaired health-related quality of life
(HR-QoL), great use of health care resources, work, and
activity impairment, resulting in substantial direct and indir-
ect costs.4,8 At the same time, negative outcomes of asthma
are associated with risk factors some of which are
modiﬁable.6
The GINA 2014 document was the ﬁrst to formally
describe asthma evaluation beyond control assessment.4
Achieving and maintaining a controlled condition is still an
important aim of asthma treatment; however, decreasing the
risks of negative outcomes caused by asthma is also a top
priority. Minimizing the risk of poor asthma outcomes,
namely future exacerbations, development of ﬁxed airﬂow
limitation, and side effects, are also aims of asthma manage-
ment. Consequently, the therapeutic strategy is not merely
determined by symptom control, but also identifying the
speciﬁc risk factors of poor asthma outcomes. Poor asthma
symptom control itself increases the risk of exacerbations.9
However, up till now, the frequency of speciﬁc risk factors
for poor asthma outcomes determined by the GINA docu-
ment, together with their relationship to disease control have
not yet been evaluated. There is no full-scale GINA deter-
mined risk factor assessment in a large asthmatic population,
either in a national or international cohort, and consequently,
no reliable data are available in respect to how much the
presence of a speciﬁc risk factor inﬂuences current control.
Our study was designed to examine not only the cur-
rent asthma control but also the importance and impact of
certain risk factors determined by the GINA document and
their relationship to uncontrolled status. Our objective was
to conduct a wide-ranging, representative real-life study in
asthma, which would provide data both on symptomatic
control level and the frequency of risk factors associated
with poor asthma outcomes in a specialist treated patient
population.
Methods
Selection of the patients
This was a non-interventional cross-sectional study under
real-life circumstances. Inclusion of the patients and data
recording was performed on a single occasion. For
detailed data collection purposes, a doctor and a patient
questionnaire were developed. In order to eliminate seaso-
nal effects, patient recruitment was carried out throughout
an entire year (from 11–05-2015 to 19–05-2016). To
obtain a non-biased patient enrolment, every health insti-
tution could include a maximum of 15 patients on 5 pre-
determined consecutive workdays per month. Enrolment
was conducted randomly with the inclusion of consecutive
asthma patients who wished to participate. Given that in
Hungary, pulmonologist specialists have the exclusive
responsibility to diagnose and treat asthma patients, the
examinations and data collection were done solely by
respiratory specialists. The enrolment of patients took
place in dispensaries, outpatient clinics specializing in
pulmonology, and in outpatient departments of hospitals
in all regions of Hungary. Table 1 contains the inclusion
and exclusion criteria of the study.
The designing and the implementation of the study
were carried out observing good clinical practice (GCP
guidelines) and the Declaration of Helsinki. Patients were
included in the study on a voluntary basis after providing
them with information and after signing a written contract,
without any remuneration.
Recorded data
A comprehensive data collection form was used to record
patient demographic characteristics, major medical history,
smoking habits, comorbidities, risk factors, current control
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
- Adult asthmatic patients
- Asthma diagnosis for
>6 months
- Maintenance therapy
unchanged in the last
month
- Out-patient
- No hospitalisation in the
last month
- No signiﬁcant, untreated
chronic disease
- Lack of consent by patient
- Inability to complete patient related
questionnaires
- Permanent need for maintenance
systemic corticosteroid treatment
- Acute exacerbations at time of
inclusion in study
- Active tuberculosis
- Malignant disease in a palliative
treatment phase
Tomisa et al Dovepress
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state, medications, and all relevant physical assessments.
Laboratory tests were not performed. Asthma control,
treatment steps, and risk factor assessment were done
according to GINA 2014 (Box 2–2 and Box 3–5.). The
treatment steps were derived from actual prescribed main-
tenance therapy. Comorbidities, allergen history, hospitali-
zation, previous intubation, low initial forced expiratory
volume in 1 s (FEV1) at the time of diagnosis, and the time
of asthma diagnosis were collected by reviewing clinical
records of enrolled patients. BMI was calculated based on
the patient’s measured height and weight at the time of
examination. Poor adherence was deﬁned by the physician
based on the patient’s data. In addition, data from the
patient survey were also documented. If spirometry was
performed on the medical visit of the patient, FEV1, forced
vital capacity (FVC), and FEV1/FVC were recorded.
Statistical analysis
Data collection and database management were conducted
by AdWare Research Ltd. (Balatonfüred, Hungary), and
the statistical analysis by Adatrendező Ltd. (Budapest,
Hungary). In the data analysis phase, descriptive statistics,
graphical outputs, and Fisher’s exact tests were used. Odds
ratios were provided with 95% conﬁdence intervals (CI).
For statistical analysis, we used the open source Python
2.7.12 on a MAC operating system (Anaconda Inc.,
Austin, TX) and R for Windows 3.4.2 (R Core Team
2017., R: A language and environment for statistical com-
puting. R Foundation for Statistical Computing, Vienna,
Austria. URL https://www.R-project.org/).
Results
During the 1-year period of inclusion, an average of 69
patients were included per investigational sites. This
involved 187 centers, representing 35% of the pulmonol-
ogists currently working in outpatient medical clinics in
Hungary. Table 2 contains the demographic data and main
clinical characteristics of the included 12743 patients.
Concerning age distribution, 9.9% of the patients were
18–30 years, 19.4% were 31–45 years, 44.6% were 46–65
years old, and 26.1% were older than 65 years. Patients
diagnosed with asthma for more than 1 year represented
97.4% of the cohort. Men represented 31.9%. With respect
to seasonality, 54.3% of the patients were examined from
April to September, while 45.7% were examined from
October to March. Patient inclusion was also in line with
population densities in the geographical regions. The
majority of patients received maintenance therapy on
GINA step 2, 3, and 4.
Patients who had never smoked represented 66.5% of
the cohort, 20.3% had smoked previously, yet quit, and
13.1% were smokers at the time of the examination. The
average body mass index (BMI) was 28.46±5.7 kg/m2.
Mean forced expiratory ﬂow in 1 s (FEV1) value was
84.29% (2.34 L), mean forced vital capacity (FVC)
94.18% (3.13 L), and mean FEV1/FVC 83.74%.
Regarding the FEV1, 38.2% of the patients had values
lower than 80% predicted, and 11.5% of the patients had
values lower than 60%.
Table 3 summarizes the medically diagnosed comor-
bidities of the whole patient population.
The most commonly recorded comorbidities (66.84% of
all patients) were rhinitis and/or sinusitis. Cardiovascular
disease was the second, affecting 43.81% of all patients.
Gastroesophageal reﬂux disease (GERD) was diagnosed in
20.11% and COPD in 7.86% of the patients.
Measuring asthma control was mandatory in all cases,
and the results are summarized in Figure 1. Well-con-
trolled asthma was found in 36.0% of the patients; how-
ever, in 29.29% of the patients, it was partially controlled,
and in 34.71% of the cases, asthma was uncontrolled.
The risk factors of poor asthma outcomes determined
by the GINA document (exacerbation, ﬁxed airway
obstruction, and side effects of medications) were also
recorded. Table 4 and Figures S1–S3 contain control
level of patients together with the speciﬁc risk factors.
Among the risk factors named by the GINA and
detected in our study, improper inhaler technique which
caused side effects showed the strongest relation to an
uncontrolled state (OR 4.86, CI 3.51–6.8). As high as
71.58% of the affected patients were uncontrolled. The
second highest OR of 4.79 was observed for patients
who had at least 1 severe exacerbation in the last 12
months; 70.05% were uncontrolled. Patients with high
short-acting beta agonist (SABA) use were also predis-
posed to loss of asthma control, with 64.55% were uncon-
trolled (OR 4.46, CI 4.03–4.93). The fourth highest OR
(3.91, CI 3.06–5.03) was found in those with incorrect
inhaler technique associated with an exacerbation.
Poor adherence to ICS showed a strong relation to
uncontrolled disease in our study as 55.11% were uncon-
trolled, resulting in an OR of 2.51 (CI 2.21–2.86). Low
FEV1 at diagnosis had an OR of 2.21 (CI 2.01–2.44) for
loss of asthma control. As an initially low FEV1 value
predisposed an uncontrolled state, an actual low FEV1 was
Dovepress Tomisa et al
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a stronger risk factor for uncontrolled disease (OR 3.14, CI
2.8–3.52).
Inhaled noxious chemicals or occupational exposures
excluding smoking affected 48.68%, who were poorly
controlled (OR 1.86, 1.6–2.15). Smoking affected 4253
patients, and poor control was present in 40.58% of them
(OR 1.47, 1.36–1.59). The most common risk factor was
the presence of chronic rhinosinusitis. A history of aller-
gies was found in 8517 patients, with similar disease
control as the whole cohort; however, out of 1786 patients
who had an allergic condition at the time of examination,
44.62% were uncontrolled and demonstrated an OR of
Table 2 Main demographic data, clinical characteristics and lung function parameters of patients
Study population
N %
Number of patients 12743 100
Number of cases in regions of Hungary East 5149 40.4
West 3984 31.3
Central 3610 28.3
Examined patients according to seasonality April–September 6923 54.3
October–March 5820 45.7
Years since the diagnosis of asthma 0–1 years 310 2.4
2–5 years 3280 25.7
6–10 years 3295 25.9
11–20 years 3930 30.8
>20 years 1913 15.0
No data 15 0.1
GINA based treatment categories STEP 1 274 2.15
STEP 2 990 7.77
STEP 3 4759 37.35
STEP 4 6390 50.14
STEP 5 330 2.59
Gender Male 4059 31.9
Female 8684 68.1
Smoking habit Smoker 1669 13.1
Former smoker 2584 20.3
Never smoked 8476 66.5
No data 14 0.1
Age distribution 18–30 1261 9.9
31–45 2466 19.4
46–65 5687 44.6
>65 3329 26.1
Body mass index distribution <18.5 228 1.8
18.5–24.9 3453 27.1
25–29.9 4487 35.2
30–34.9 3009 23.6
≥35 1566 12.3
FEV1 (forced expiratory volume in 1 s, % predicted) distribution >80% 7527 59.1
60–80% 3399 26.7
<60% 1461 11.5
No data 356 2.8
Abbreviation: GINA, global initiative for asthma.
Tomisa et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Journal of Asthma and Allergy 2019:12300
 
Jo
ur
na
l o
f A
st
hm
a 
an
d 
Al
le
rg
y 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
3.
22
4.
49
.5
0 
on
 2
4-
Se
p-
20
19
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
1.63 (1.47–1.81) for loss of asthma control. In 1513
patients, systemic corticosteroid treatment was necessary,
and poor asthma control was observed in 47.46% of them.
Frequent OCS related to systemic side effects resulted in a
high uncontrolled level (OR 1.83, 1.64–2.05). In 4575
cases, the BMI was >30 kg/m2, and 39.04% of these
patients were poorly controlled (OR 1.34, CI 1.24–1.45).
Discussion
In Hungary, similarly to many countries of Eastern
Europe, the diagnosis and treatment of asthmatic
patients is the responsibility of the pulmonologists. A
whole range of therapeutic options suggested by the
GINA guidelines is available. Nonetheless, based on
the current study, which was the largest study examining
asthma control in Eastern Europe, 36% of the patients
were well controlled, 29.29% were partially controlled,
and 34.71% were uncontrolled.
Regarding the rate of controlled asthma, our investiga-
tion demonstrated nearly equivalent result to a recent
specialist-based cross-sectional study of adult asthma in
Japan. Adachi et al found, despite receiving treatment
from an allergy and/or respiratory specialist, only 35.1%
of the patients had controlled asthma.10 In Turkey,
Gemicioglu et al observed the same rate of controlled
patients. The percentage of patients with total control in
the elderly and young groups were 33.9% and 37.1% at
ﬁrst visit.11 These results draw attention to the need for
improving asthma management. There is growing evi-
dence that environmental pollution aggravates asthma.
One limitation is that this factor has not been studied.12
Uncontrolled disease may be related to the presence of
risk factors documented by the GINA guidelines. This
current study was the ﬁrst large-scale, specialist-evaluated
cohort which aimed to determine the frequency of speciﬁc
risk factors identiﬁed by the GINA document. Our aim
was to validate the known risk factors of non-control in a
large asthma cohort in real life. Based on the data collected
by pulmonologists during patient visits, GINA deﬁned risk
factors for poor asthma outcomes proved to be related to
uncontrolled disease; the strength of this relationship var-
ied depending on the risk factor. In everyday clinical
practice, it is important to know that the frequencies and
the relationships to poor control of listed risk factors vary
over a wide range.
The frequency of speciﬁc risk factors and the odds
ratio of its relationship with control loss are visualized in
Figure 2. The risk factors that appear more frequently than
average and those which strongly linked to a poor outcome
should be prioritized and monitored continuously.
In our study, besides excessive SABA use, yearly
exacerbating disease pattern, improper inhaler technique,
and low FEV1 (<60% predicted) were the most strongly
related to suboptimal disease control. It was not surprising
that high SABA use had an especially high OR. Of the
patients who used more than 1 pack of salbutamol a
month, 64.55% were uncontrolled at the time of the sur-
vey, and in total only 13% of them were well controlled.
This result clearly shows that there is an overuse of sal-
butamol that is related to uncontrolled disease.
Similarly to high SABA use, the chance of an uncon-
trolled status (eg, exacerbations) amongst patients who had
at least 1 severe exacerbation per year was exceedingly
high. This conﬁrms the results of the TENOR Study Group
Table 3 Comorbidities of study participants (data are presented
as numbers and percentages)
Comorbidities N %
Cardiovascular disease 5583 43.81
Hypertension 5226 41.01
Cardiac insufﬁciency 1250 9.81
Acute myocardial infarction 210 1.65
Atrial ﬁbrillation (chronic) 160 1.26
Other cardiac arrhythmia 731 5.70
Other cardiac history 215 1.69
Rhinitis and/or Sinusitis 8517 66.84
Gastroesophageal reﬂux disease (GERD) 2563 20.11
Diabetes 1129 8.86
Impaired glucose tolerance (IGT) 1058 8.30
Concomitant COPD 1002 7.86
Osteoporosis 1081 8.48
Prostate hyperplasia 317 2.49
Glaucoma 227 1.78
Cerebrovascular events 311 2.44
Other comorbidities 1320 10.36
Well-controlled
36.0%
Partly 
controlled
29.3%
Uncontrolled
34.7%
Well-controlled Partly controlled Uncontrolled
Figure 1 Proportion of patients with different levels of asthma control according to
GINA guideline.
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that severe asthma exacerbations are a strong independent
factor predicting future exacerbations.13 Although patients
in acute exacerbation were excluded from our study,
5.11% of the patients had severe exacerbation within the
last year, and 70.05% of them were poorly controlled at
the time of the study.
Incorrect inhaler technique was recorded in two
aspects listed in the GINA guideline. In the present
study, incorrect inhaler technique showed a strong rela-
tionship to uncontrolled status. This is in line with a
recent study, which showed that incorrect inhaler tech-
nique seems to be frequent in real-life settings. Melani
et al found that 12–43.5% of the patients make at least 1
critical error in inhalation technique, and hospitalization
or emergency department visit due to these errors
occurred in 30% of the patients.14 The study showed
that different failures of device use may lead to different
levels of impairment to successful therapy. Incorrect
inhaler technique in real-life setting may be an impor-
tant risk factor to loss of control (named as poor asthma
outcome in our study) and also exacerbations, because
poor inhaler technique may cause low drug deposition
resulting in deterioration of the effect of the drug. On
the other hand, improper inhaler technique may worsen
drug adherence. Thus, educational programs, which are
inexpensive and effective, may help in preventing the
development of loss of asthma control.15,16
Data recording of incorrect inhaler technique on the
other hand represents a limitation of our study, as it was
the doctors’ task to determine inhalation technique, and also
whether the patient had an exacerbation or side effect due to
incorrect inhaler technique. GINA underlines the fact that
low FEV1 is known to be a strong independent predictor of
future exacerbations. Our results are in concordance with
these ﬁndings, both when low FEV1 was measured at the
time of diagnosis or with maintenance therapy. However,
our results raise a hypothesis that patients are at higher risk
of poor outcomes if their low FEV1 exists despite the use of
maintenance therapy. Although we experienced low FEV1
in only 11.47% of our patients, it may be considered as a
very strong predictor of uncontrolled status with an OR of
3.14. Interestingly, low initial FEV1 values also showed a
signiﬁcant relationship to loss of asthma control, with an
OR of 2.21. Our results were consistent with those of
Osborne and co-workers, who found that patients with
low FEV1 at any time of their life are at a signiﬁcantly
higher risk of exacerbations, which underscores the impor-
tance of spirometry in asthma care.17
Notably in our study, the incidence of frequent OCS
users was high, and despite the effective systemic effect
of this medication, their control was signiﬁcantly lower than
average. In the CHAS study, Gonzalez et al observed a high
level of uncontrolled asthma (63.9%) which was strongly
associated with oral corticosteroid treatment (OR=6.55).18
Excessive SABA use
Poor adherence
Incorrect inhaler technique in connection 
with exacerbation
Low FEV1 <60% predicted (actual)
Obesity (above BMI 30)Allergen exposure if sensitized (in the 
patient's allergic season)Pregnancy
Ever intubated or in intensive care unit for 
asthma
≥1 Severe exacerbation in last 12 months
Lack of ICS treatment
Tobacco smoke (history of active smoking)
Noxious chemicals or occupational 
exposures
Low initial FEV1 (<60% predicted)
Frequent OCS
P450 inhibitor
No proper inhaler technique which caused 
side effect
0.50
1.50
2.50
3.50
4.50
5.50
0.00% 5.00% 10.00% 15.00% 20.00% 25.00% 30.00% 35.00% 40.00%
O
dd
s 
ra
tio
Frequency of risk factor (%)
Figure 2 The frequency of speciﬁc risk factors and the odds ratio of its relationship with uncontrolled status.
Note: Size of bubbles represent the ratio of uncontrolled patients.
Abbreviations: BMI, body mass index; ICS, ICS, inhaled corticosteroid; OCS, oral corticosteroid; FEV1, forced expiratory volume in 1s; SABA, short-acting beta agonist.
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In our investigation, the incidence of poor adherence to
treatment was lower than in other speciﬁc adherence-
focused studies.19,20 Our method had limitations in recog-
nizing all non-adherent patients, which may be the conse-
quence of deﬁciencies in the collection of adherence data
by specialists in everyday clinical practice. However, our
results still conﬁrmed the well-established evidence of
poor adherent patients having a high probability of an
uncontrolled status.21
Three risk factors were identiﬁed in our study affecting
a high number of patients but having a weaker relationship
with loss of asthma control. The smoker group represented
33.38% of all the patients and was related to suboptimal
control with an OR of 1.47. Smoking is a frequent factor
behind suboptimal asthma control, with the risk of evol-
ving COPD. Among smokers, 13.1% of the patients were
currently active smokers and their OR was 1.58 (CI 1.42–
1.76). Consequently, active smoking may be considered as
a frequent factor behind suboptimal asthma control.
Furthermore, for ex-smokers, the chance of poor outcome
remains higher for a long time after quitting.
Many studies support an association between obesity
and asthma prevalence.22–28 It has also been proved that
patients with obesity are more likely to have uncontrolled
asthma compared to eutrophic patients.29 Additionally, an
association between obesity and increased asthma severity
in adults has been demonstrated.30 The National Asthma
Survey, one of the largest asthma surveys in the USA,
showed that obesity is associated with several measures
of asthma severity and control, including symptoms,
missed workdays, medication use, and GINA severity
classiﬁcation.31 In our study, the risk of an uncontrolled
status was also higher due to obesity.
A history of rhinosinusitis or food allergy was especially
prevalent amongst Hungarian asthmatic patients; however, it
showed no strong relationship with poor asthma outcomes.
Inhaled allergens cause problems and symptoms at a speciﬁc
time of the year. Therefore, we separately analyzed the patient
group who had seasonal allergies at the time of data registra-
tion. Out of 1786 patients who were examined in their sensi-
tized allergen period, 44.62% had bad asthma control, which
was higher compared to the rest of the patients and correlated
signiﬁcantly with a higher chance for bad asthma outcomes. A
limitation of our study is that bronchiectasis was not actively
screened, which could impact on control status of moderate to
severe asthma patients.32 Finally, we identiﬁed infrequent risk
factors aswellwhichwere less likely toworsen asthma control.
Patients who had been pregnant in the last 12 months repre-
sented 0.34% of the cohort, but this condition had hardly any
effect on current asthma control. At the time of enrolment, 43
patients were pregnant; however, due to the smaller number of
participants, it was not possible to reliably determine what
effect pregnancy had on current asthma state. The rate of the
side effects that stem from the co-administration of a P450
inhibitor compared to the examined risk factors is still an
important result despite its lower incidence. The risk of uncon-
trolled asthma was not associated with a lack of ICS. The
reason for this may be that pulmonologists underestimate the
lack of ICS resulting from non-adherence. On the other hand,
there could be a patient population who used maintenance
therapy as needed without losing control of their asthma.
This hypothesis was supported by Papi et al, who found that
patients with mild persistent asthma who have infrequent
symptoms may not require regular treatment with inhaled
corticosteroids.33
Conclusion
The results of this large real-world study, conducted for the
ﬁrst time in Eastern Europe by respiratory specialists, may
contribute to uncovering the most important causes of poor
asthma control in everyday clinical practice, together with
determining the impact of different risk factors in leading to
poor asthma outcomes, thus gaining a better understanding of
the disease. We found that the risk factors listed by the GINA
document signiﬁcantly inﬂuence the control level of asth-
matic patients. High SABA use, exacerbation history, incor-
rect inhaler technique, persistently low FEV1, and poor
adherence to treatment are of outstanding signiﬁcance in
inﬂuencing asthma control and leading to poor outcomes.
In order to further improve disease control, substantial atten-
tion might be paid to recognizing risk factors for poor asthma
outcomes.
Abbreviation list
OR, odds ratio; CI, conﬁdence intervals; COPD, chronic
obstructive pulmonary disease; GINA, Global Initiative
for Asthma; HR-QoL, health-related quality of life;
eCRF, electronic case report form; GCP, good clinical
practice; FEV1, forced expiratory volume in 1 s; FVC,
forced vital capacity; BMI, body mass index; GERD,
gastroesophageal reﬂux disease; IGT, Impaired glucose
tolerance; SABA, short-acting beta agonist; ICS, inhaled
corticosteroid, ICU, intensive care unit.
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Risk factors Odds ratios (95% CI)
Figure S1 - Risk factors for exacerbation 
Excessive SABA use (> 1 pack / month)
Inadequate ICS (not prescribed ICS, poor adherence, no proper inhaler technique)
Poor adherence
Incorrect inhaler technique in connection with exacerbation
Low FEV1 <60% predicted (actual)
Exposures (smoking, allergen exposure if sensitized)
Comorbidities (Overweight, rhinosinusitis, confirmed food allergy)
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≥1 severe exacerbation in last 12 months
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Figure S1 Risk factors for exacerbation.
Figure S2 - Risk factors for developing fixed airflow limitation 
Lack of ICS treatment
Exposures (Tobacco smoke, noxious chemicals, occupational exposures)
Tobacco smoke (history of active smoking)
Smoking (currently active smokers)
Noxious chemicals or occupational exposures
Low initial FEV1 (<60% predicted)
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Figure S2 Risk factors for developing ﬁxed airﬂow limitation.
Figure S3 - Risk factors for medication side effects
Systemic side effect
Frequent OCS
P450 inhibitor
No proper inhaler technique which caused side effect
0 1 2 3 4 5 6 7
Figure S3 Risk factors for medication side effects.
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